These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12756103)

  • 1. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease.
    Plettenberg H; Assmann T; Ruzicka T
    Arch Dermatol; 2003 May; 139(5):651-4. PubMed ID: 12756103
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical tacrolimus for treatment of childhood vitiligo in Asians.
    Kanwar AJ; Dogra S; Parsad D
    Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of vitiligo with 0.1% tacrolimus ointment.
    Travis LB; Weinberg JM; Silverberg NB
    Arch Dermatol; 2003 May; 139(5):571-4; discussion 573. PubMed ID: 12756092
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure.
    Ostovari N; Passeron T; Lacour JP; Ortonne JP
    Arch Dermatol; 2006 Feb; 142(2):252-3. PubMed ID: 16490866
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color.
    Silverberg JI; Silverberg NB
    J Drugs Dermatol; 2011 May; 10(5):507-10. PubMed ID: 21533297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment.
    Ahn BK; Kim BD; Lee SJ; Lee SH
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):532-3. PubMed ID: 15761441
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
    Zehtab T; Yazdanparast R; Rafieii S
    Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tacrolimus on vitiligo in absence of UV radiation exposure.
    Sardana K; Bhushan P; Kumar Garg V
    Arch Dermatol; 2007 Jan; 143(1):119; author reply 120. PubMed ID: 17224558
    [No Abstract]   [Full Text] [Related]  

  • 9. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with tacrolimus in autoimmune diseases].
    Sádaba B; Azanza JR; García Quetglas E; Fernández V
    Rev Med Univ Navarra; 2004; 48(3):24-38. PubMed ID: 15622922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream.
    Souza Leite RM; Craveiro Leite AA
    Int J Dermatol; 2007 Sep; 46(9):986-9. PubMed ID: 17822508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Symptomatic tapetoretinal degeneration in pigment disorders of the skin: approaches to understanding the pathomechanism and therapy].
    Krastel H; Anton-Lamprecht I; Alexandridis E; Tilgen W
    Fortschr Ophthalmol; 1985; 82(6):562-70. PubMed ID: 4093108
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo.
    Sehgal VN
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1218-9. PubMed ID: 19192018
    [No Abstract]   [Full Text] [Related]  

  • 14. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.
    Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS
    J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunopathogenic aspects and principles of immunomodulation therapy in autoimmune and chronic connective tissue diseases].
    Dobloug JH; Førre O; Mellbye OJ; Refsum SB; Christoffersen T
    Tidsskr Nor Laegeforen; 1983 Apr; 103(10):823-8. PubMed ID: 6879516
    [No Abstract]   [Full Text] [Related]  

  • 16. Vitiligo.
    Paterson E
    J Vis Commun Med; 2010 Dec; 33(4):166-8. PubMed ID: 21087187
    [No Abstract]   [Full Text] [Related]  

  • 17. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
    Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS
    Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
    Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
    J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
    Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
    Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal acne during topical tacrolimus therapy for vitiligo.
    Bakos L; Bakos RM
    Arch Dermatol; 2007 Sep; 143(9):1223-4. PubMed ID: 17875902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.